Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance

Behavioural Pharmacology

Volumn 11, Issue 3-4, 2000, Pages 307-316

  Murphy, C A ^a   Feldon, J ^b  

^a ETH ZURICH   (Switzerland)

^b NONE

Author keywords

Antipsychotics; Avoidance; Catalepsy; Clozapine; Ext rapyramidal motor symptoms; Haloperidol; Neuroleptics; Rat

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; COMPARATIVE STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; RAT;

EID: 0033923055     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200006000-00014     Document Type: Article

References (57)

1. Anisman H, Corradini A, Tombaugh TN, Zacharko RM (1982). Avoidance performance, cue and response-choice discrimination after neuroleptic treatment. Pharmacol Biochem Behav 17:1245-1249.
2. Arnt J (1982). Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321-329.
3. Baldessarini RJ (1985). Drugs and the treatment of psychiatric disorders. In: The Pharmacological Basis of Therapeutics. 7th ed. Gilman AG, Goodman LS, Rall TW, Murad F (editors). New York: Macmillan, pp. 387-445.
4. Baldessarini RJ, Frankenburg FR (1991). Clozapine. A novel antipsychotic agent. N Engl J Med 324:746-754.
5. Balsara JJ, Jadhav JH, Chandorkar AG (1979). Effects of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67-69.
6. Barnes DE, Robinson B, Csernansky JG, Bellows EP (1990). Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol Biochem Behav 36:883-887.
7. Bartholini G (1976). Differential effects of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28:429-433.
8. Bartoszyk GD, Roos C, Ziegler H (1996). 5-HT1a receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 35:1645-1646.
9. Beninger RJ, Mason ST, Phillips AG, Fibiger HC (1980). The use of conditioned suppression to evaluate the nature of neuroleptic-induced avoidance deficits. J Pharmacol Exp Ther 213:623-627.
10. Blackburn JR, Phillips AG (1989). Blockade of acquisition of one-way conditioned avoidance responding by haloperidol and metoclopramide but not by thioridazine or clozapine: implications for screening new antipsychotic drugs. Psychopharmacology 98:453-459.
11. Bruhwyler J, Chleide E, Mercier M (1990). Clozapine: An atypical neuroleptic. Neurosci Biobehav Rev 14:357-363.
12. Casey DE (1989). Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53.
13. Deutch AY (1996). The mechanisms of action of antipsychotic drugs as revealed by immediate-early gene expression. In: Antipsychotics (Handbook of Experimental Pharmacology, vol. 120). Csernansky JG (editor). Berlin: Springer, pp. 117-161.
14. Fibiger HC, Mason ST (1978). The effects of dorsal bundle injections of 6-hydroxydopamine on avoidance responding in rats. Br J Pharmacol 64:601-605.
15. Fibiger HC, Phillips AG, Zis AP (1974). Deficits in instrumental responding after 6-hydroxydopamine lesions of the nigro-neostriatal dopaminergic projection. Pharmacol Biochem Behav 2:87-96.
16. Fibiger HC, Zis AP, Phillips AG (1975). Haloperidol-induced disruption of conditioned avoidance responding: attenuation by prior training or by anticholinergic drugs. Eur J Pharmacol 30:309-314.
17. Haubrich DR, Wang PFL, Herman RL, Clody DE (1975). Acetylcholine synthesis in rat brain: dissimilar effects of clozapine and chlorpromazine. Life Sci 17:739-748.
18. 2 adrenoceptor blockade. Science 286:105-107.
19. Hoffman DC, Donovan H (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal effects. Psychopharmacology 120:128-133.
20. Iorio LC, Cohen M, Coffin VL (1991). Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats. J Pharmacol Exp Ther 258:118-123.
21. Juul Povlsen U, Noring U, Fog R, Gerlach J (1985). Tolerabiliry and therapeutic effect of clozapine. Acta Psychiatr Scand 71:176-185.
22. Kalkman HO, Neumann V, Tricklebank MD (1997). Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn-Schmeideberg's Arch Pharmacol 355:361-364.
23. Kalkman HO, Neumann V, Hoyer D, Tricklebank MD (1998). The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556.
24. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
25. Kinon BJ, Lieberman JA (1996). Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2-34.
26. Kuribara H, Sakutaro T (1980). Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 14:181-192.
27. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131:57-63.
28. MacGibbon GA, Lawlor PA, Bravo R, Dragunow M (1994). Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol Brain Res 23:21-32.
29. Mason ST, Roberts DCS, Fibiger HC (1978). Noradrenergic influences on catalepsy. Psychopharmacology 60:53-57.
30. Migler BM, Warawa EJ, Malick JB (1993). Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 112:299-307.
31. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H (1997). Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58 (suppl 10):37-44.
32. Neill DB, Boggan WO, Grossman SP (1974). Impairment of avoidance performance by intrastriatal administration of 6-hydroxydopamine. Pharmacol Biochem Behav 2:97-103.
33. Niemegeers CJE, Verbruggen FJ, Janssen PAJ (1969). The influence of various neuroleptic drugs on shock avoidance responding in rats. Psychopharmacologia 16:161-174.
34. Ogren SO, Archer T (1994). Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile. Psychopharmacology 114:383-391.
35. Pakkenberg H, Pakkenberg B (1986). Clozapine in the treatment of tremor. Acta Neurol Scand 73:295-297.
36. Posluns D (1962). An analysis of chlorpromazine-induced suppression of the avoidance response. Psychopharmacology 3:361-373.
37. Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328.
38. Sanberg PR (1980). Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284:472-473.
39. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988). The catalepsy test: its ups and downs. Behav Neurosci 102:748-759.
40. Sanger DJ (1985) The effects of clozapine on shuttle-box avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 23:231-236.
41. Sanger DJ (1986). Response decrement patterns after neuroleptic and non-neuroleptic drugs. Psychopharmacology 89:98-104.
42. Sayers AC, Burki HR, Ruch W, Asper H (1976). Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology 51:15-22.
43. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Compel P, Lesage AS et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
44. Seeman P, Tallerico T (1999). Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876-884.
45. Selby G (1990). Clinical features. In: Parkinson's Disease. Stern GM (editor). London: Chapman and Hall, pp. 333-388.
46. Setler P, Sarau H, McKenzy G (1976). Differential attenuation of some effects of haloperidol in rats given scopolamine. Eur J Pharmacol 39:117-126.
47. Shopsin B, Klein H, Aaronson M, Collora M (1979). Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. A controlled, double-blind comparison. Arch Gen Psychiatry 36:657-664.
48. Snyder SH, Greenberg D, Yamamura HI (1974). Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 31:58-61.
49. Taboada ME, Souto M, Hawkins H, Monti JM (1979). The actions of dopaminergic and noradrenergic antagonists on conditioned avoidance responses in intact and 6-hydroxydopamine-treated rats. Psychopharmacology 62:83-88.
50. Tang AH, Franklin SR, Himes CS, Smith MW, Tenbrink RE (1997). PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther 281:440-447.
51. Wadenberg ML, Seeman P (1999). Clozapine pre-treatment enhances raclopride catalepsy. Eur J Pharmacol 377: R1-2.
52. Wadenberg M-L, Ahlenius S, Svensson TH (1993). Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology 110:273-279.
53. 6 receptors following antipsychotic administration. Neuroscience 89:927-938.
54. Wirtshafter D (1998). Clozapine antagonizes the induction of striatal Fos expression by typical neuroleptics. Eur J Pharmacol 358:R1-3.
55. Wise RA (1982). Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 5:39-87.
56. Young CD, Bubser M, Meltzer HY, Deutsch AY (1999). Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Psychopharmacology 144:255-263.
57. Zis AP, Fibiger HC, Phillips AG (1974). Reversal by L-DOPA of impaired learning due to destruction of the dopaminergic nigro-neostriatal projection. Science 185:960-962.